STAAR Surgical preliminary Q1 net sales >$77M; record US ICL sales of $5M, up 20% sequentially

STAAR SURGICAL CO

2024-Q1 EPS reported -$0.07 revenue$77,356,000

Preliminary Q1 2024 net sales in excess of $77M; US ICL sales hit record $5M, up ~20% sequentially.
EMEA ICL sales up ~11% YoY; APAC ICL sales up ~9% including ~10% growth in China.
Cash and investments ~$248M (Dec 2023: $232.4M); accounts receivable ~$70M (Dec 2023: $94.7M).
Fiscal 2024 net sales outlook now expected at higher end of $335M-$340M range.
Full Q1 results and 2024 outlook to be discussed on earnings call on/about May 8, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue in excess of $77 million.

Period: first quarter ended March 29, 2024
Revenue: in excess of $77 million
Result: preliminary results

Exact text from the filing

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million, with U.S. ICL sales expected to be $5 million for the quarter.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

STAAR SURGICAL CO filing history →

Source: SEC EDGAR

accession 0000950170-24-041613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.